Header Logo

Glen Weiss MD, MBA

TitleAssociate Professor
InstitutionUMass Chan Medical School
DepartmentMedicine
AddressUMass Chan Medical School
55 Lake Avenue North
Worcester MA 01655
Phone508-334-1000
vCardDownload vCard
    Other Positions
    InstitutionT.H. Chan School of Medicine
    DepartmentMedicine


    Collapse Biography 
    Collapse education and training
    Rutgers University- New Brunswick, New Brunswick, NJ, United StatesBABiological Sciences
    Arizona State University, Tempe, AZ, United StatesMBA
    Sackler School of Medicine, Tel Aviv, , IsraelMD

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Hickman TL, Choi E, Whiteman KR, Muralidharan S, Pai T, Johnson T, Parikh A, Friedman T, Gilbert M, Shen B, Barron L, McGinness KE, Ettenberg SA, Motz GT, Weiss GJ, Jensen-Smith A. BOXR1030, an anti-GPC3 CAR with exogenous GOT2 expression, shows enhanced T cell metabolism and improved anti-cell line derived tumor xenograft activity. PLoS One. 2022; 17(5):e0266980. PMID: 35507536.
      Citations:    Fields:    Translation:HumansCells
    2. Ho TH, Pfeffer K, Weiss GJ, Ruiz Y, Lake DF. Identification of a CD4+ T cell line with Treg-like activity. Hum Immunol. 2022 Apr; 83(4):281-294. PMID: 35094878.
      Citations:    Fields:    Translation:HumansCells
    3. Marfil-Sánchez A, Seelbinder B, Ni Y, Varga J, Berta J, Hollosi V, Dome B, Megyesfalvi Z, Dulka E, Galffy G, Weiss GJ, Panagiotou G, Lohinai Z. Gut microbiome functionality might be associated with exercise tolerance and recurrence of resected early-stage lung cancer patients. PLoS One. 2021; 16(11):e0259898. PMID: 34793492.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    4. Patnaik A, Weiss GJ, Rasco DW, Blaydorn L, Mirabella A, Beeram M, Guo W, Lu S, Danaee H, McEachern K, Im E, Sachdev JC. Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial. Cancer Chemother Pharmacol. 2022 01; 89(1):93-103. PMID: 34750637.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    5. Oo HZ, Lohinai Z, Khazamipour N, Lo J, Kumar G, Pihl J, Adomat H, Nabavi N, Behmanesh H, Zhai B, Dagil R, Choudhary S, Gustavsson T, Clausen TM, Esko JD, Allen JW, Thompson MA, Tran NL, Moldvay J, Dome B, Salanti A, Al-Nakouzi N, Weiss GJ, Daugaard M. Oncofetal Chondroitin Sulfate Is a Highly Expressed Therapeutic Target in Non-Small Cell Lung Cancer. Cancers (Basel). 2021 Sep 06; 13(17). PMID: 34503301.
      Citations:    
    6. Addeo A, Friedlaender A, Banna GL, Weiss GJ. TMB or not TMB as a biomarker: That is the question. Crit Rev Oncol Hematol. 2021 Jul; 163:103374. PMID: 34087341.
      Citations: 17     Fields:    Translation:Humans
    7. Ni Y, Lohinai Z, Heshiki Y, Dome B, Moldvay J, Dulka E, Galffy G, Berta J, Weiss GJ, Sommer MOA, Panagiotou G. Distinct composition and metabolic functions of human gut microbiota are associated with cachexia in lung cancer patients. ISME J. 2021 11; 15(11):3207-3220. PMID: 34002024.
      Citations: 3     Fields:    Translation:HumansCells
    8. Mirhakkak MH, Schäuble S, Klassert TE, Brunke S, Brandt P, Loos D, Uribe RV, Senne de Oliveira Lino F, Ni Y, Vylkova S, Slevogt H, Hube B, Weiss GJ, Sommer MOA, Panagiotou G. Metabolic modeling predicts specific gut bacteria as key determinants for Candida albicans colonization levels. ISME J. 2021 05; 15(5):1257-1270. PMID: 33323978.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    9. Cambridge CL, Gatof ES, Weiss GJ, Davis RB. Financial Conflicts of Interest Change After a High-Impact Clinical Trial Publication in Oncology. J Patient Cent Res Rev. 2020; 7(3):249-254. PMID: 32760756.
      Citations:    
    10. Sehgal K, Bulumulle A, Brody H, Gill RR, Macherla S, Qilleri A, McDonald DC, Cherry CR, Shea M, Huberman MS, VanderLaan PA, Weiss GJ, Walker PR, Costa DB, Rangachari D. Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non-small-cell Lung Cancer. Clin Lung Cancer. 2021 05; 22(3):e379-e389. PMID: 32653295.
      Citations: 5     Fields:    Translation:Humans
    11. Heshiki Y, Vazquez-Uribe R, Li J, Ni Y, Quainoo S, Imamovic L, Li J, Sørensen M, Chow BKC, Weiss GJ, Xu A, Sommer MOA, Panagiotou G. Predictable modulation of cancer treatment outcomes by the gut microbiota. Microbiome. 2020 03 05; 8(1):28. PMID: 32138779.
      Citations: 38     Fields:    Translation:HumansAnimalsCells
    12. Friedlaender A, Drilon A, Weiss GJ, Banna GL, Addeo A. KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures. Cancer Treat Rev. 2020 Apr; 85:101978. PMID: 32062493.
      Citations: 31     Fields:    Translation:Humans
    13. Papadopoulos KP, Johnson ML, Lockhart AC, Moore K, Falchook GS, Formenti SC, Naing A, Carvajal RD, Rosen LS, Weiss GJ, Leidner RS, Li J, Paccaly A, Feng M, Stankevich E, Lowy I, Fury MG, Crittenden MR. First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies. Clin Cancer Res. 2020 03 01; 26(5):1025-1033. PMID: 31796520.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    14. Addeo A, Banna GL, Weiss GJ. Tumor Mutation Burden-From Doubts to Concerns-In Reply. JAMA Oncol. 2019 12 01; 5(12):1809. PMID: 31647493.
      Citations: 2     Fields:    Translation:Humans
    15. Lohinai Z, Megyesfalvi Z, Dome B, Weiss GJ. Next-Generation Sequencing May Discriminate Extreme Long-term versus Short-term Survival in Patients with Metastatic Small Cell Lung Cancer (SCLC). Transl Oncol. 2019 Dec; 12(12):1539-1548. PMID: 31476386.
      Citations:    
    16. Weiss GJ, Blaydorn L, Beck J, Bornemann-Kolatzki K, Urnovitz H, Schütz E, Khemka V. Correction to: Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma. Invest New Drugs. 2019 Aug; 37(4):797. PMID: 31020607.
      Citations: 2     Fields:    
    17. Addeo A, Weiss GJ. Measuring tumor mutation burden in cell-free DNA: advantages and limits. Transl Lung Cancer Res. 2019 Aug; 8(4):553-555. PMID: 31555531.
      Citations:    
    18. Lohinai Z, Bonanno L, Aksarin A, Pavan A, Megyesfalvi Z, Santa B, Hollosi V, Hegedus B, Moldvay J, Conte P, Ter-Ovanesov M, Bilan E, Dome B, Weiss GJ. Neutrophil-lymphocyte ratio is prognostic in early stage resected small-cell lung cancer. PeerJ. 2019; 7:e7232. PMID: 31392087.
      Citations:    
    19. Addeo A, Banna GL, Weiss GJ. Tumor Mutation Burden-From Hopes to Doubts. JAMA Oncol. 2019 Jul 01; 5(7):934-935. PMID: 31145420.
      Citations: 51     Fields:    Translation:Humans
    20. Lin CC, Arkenau HT, Lu S, Sachdev J, de Castro Carpeño J, Mita M, Dziadziuszko R, Su WC, Bobilev D, Hughes L, Chan J, Zhang ZY, Weiss GJ. A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas. Br J Cancer. 2019 07; 121(2):131-138. PMID: 31217479.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    21. Addeo A, Weiss GJ, Gyawali B. Association of Industry and Academic Sponsorship With Negative Phase 3 Oncology Trials and Reported Outcomes on Participant Survival: A Pooled Analysis. JAMA Netw Open. 2019 05 03; 2(5):e193684. PMID: 31074821.
      Citations: 2     Fields:    Translation:Humans
    22. Weiss GJ, Addeo A. Atezolizumab plus Chemotherapy in Small-Cell Lung Cancer. N Engl J Med. 2019 02 28; 380(9):888-889. PMID: 30811920.
      Citations: 1     Fields:    Translation:Humans
    23. Weiss GJ, Davis RB. Discordant financial conflicts of interest disclosures between clinical trial conference abstract and subsequent publication. PeerJ. 2019; 7:e6423. PMID: 30775185.
      Citations:    
    24. Weiss GJ. A new era of treating advanced lung cancer is upon us. Transl Lung Cancer Res. 2018 Sep; 7(Suppl 3):S202-S205. PMID: 30393601.
      Citations:    
    25. Morris SM, Subramanian J, Gel ES, Runger GC, Thompson EJ, Mallery DW, Weiss GJ. Correction: Performance of next-generation sequencing on small tumor specimens and/or low tumor content samples using a commercially available platform. PLoS One. 2018; 13(6):e0200224. PMID: 29953541.
      Citations:    Fields:    
    26. Morris SM, Subramanian J, Gel ES, Runger GC, Thompson EJ, Mallery DW, Weiss GJ. Performance of next-generation sequencing on small tumor specimens and/or low tumor content samples using a commercially available platform. PLoS One. 2018; 13(4):e0196556. PMID: 29702695.
      Citations: 9     Fields:    Translation:Humans
    27. Morris S, Vachani A, Pass HI, Rom WN, Ryden K, Weiss GJ, Hogarth DK, Runger G, Richards D, Shelton T, Mallery DW. Whole blood FPR1 mRNA expression predicts both non-small cell and small cell lung cancer. Int J Cancer. 2018 06 01; 142(11):2355-2362. PMID: 29313979.
      Citations: 6     Fields:    Translation:Humans
    28. Ramanathan RK, Weiss GJ, Posner RG, Rajeshkumar NV, Jameson G, Aziz M, Hoering A, Bolejack V, Maitra A, Fulk M, Stites EC, Hlavacek WS, Gatalica Z, Xiu J, Hidalgo M, Von Hoff DD, Barrett MT. A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients. J Gastrointest Oncol. 2017 Dec; 8(6):925-935. PMID: 29299351.
      Citations:    
    29. Mitchell S, Williams JP, Bhatti H, Kachaamy T, Weber J, Weiss GJ. A retrospective matched cohort study evaluating the effects of percutaneous endoscopic gastrostomy feeding tubes on nutritional status and survival in patients with advanced gastroesophageal malignancies undergoing systemic anti-cancer therapy. PLoS One. 2017; 12(11):e0188628. PMID: 29186164.
      Citations:    Fields:    Translation:Humans
    30. Weiss GJ, Blaydorn L, Beck J, Bornemann-Kolatzki K, Urnovitz H, Schütz E, Khemka V. Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma. Invest New Drugs. 2018 02; 36(1):96-102. PMID: 29119276.
      Citations: 73     Fields:    Translation:HumansCTClinical Trials
    31. Lam ET, Eckhardt SG, Messersmith W, Jimeno A, O'Bryant CL, Ramanathan RK, Weiss GJ, Chadha M, Oey A, Ding HT, Culp PA, Keller SF, Zhao VY, Tsao LC, Singhal A, Holen KD, Von Hoff D. Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors. Mol Cancer Ther. 2018 01; 17(1):215-221. PMID: 29054986.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    32. Weiss GJ, Jameson G, Von Hoff DD, Valsasina B, Davite C, Di Giulio C, Fiorentini F, Alzani R, Carpinelli P, Di Sanzo A, Galvani A, Isacchi A, Ramanathan RK. Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors. Invest New Drugs. 2018 02; 36(1):85-95. PMID: 28726132.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    33. Weiss GJ, Lohinai Z. Prophylactic cranial irradiation in small-cell lung cancer. Lancet Oncol. 2017 07; 18(7):e367. PMID: 28677570.
      Citations:    Fields:    Translation:Humans
    34. Weiss GJ, Byron SA, Aldrich J, Sangal A, Barilla H, Kiefer JA, Carpten JD, Craig DW, Whitsett TG. A prospective pilot study of genome-wide exome and transcriptome profiling in patients with small cell lung cancer progressing after first-line therapy. PLoS One. 2017; 12(6):e0179170. PMID: 28586388.
      Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
    35. Weiss GJ, Waypa J, Blaydorn L, Coats J, McGahey K, Sangal A, Niu J, Lynch CA, Farley JH, Khemka V. A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus). Br J Cancer. 2017 Jun 27; 117(1):33-40. PMID: 28588322.
      Citations: 52     Fields:    Translation:HumansCTClinical Trials
    36. Bahleda R, Grilley-Olson JE, Govindan R, Barlesi F, Greillier L, Perol M, Ray-Coquard I, Strumberg D, Schultheis B, Dy GK, Zalcman G, Weiss GJ, Walter AO, Kornacker M, Rajagopalan P, Henderson D, Nogai H, Ocker M, Soria JC. Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies. Br J Cancer. 2017 Jun 06; 116(12):1505-1512. PMID: 28463960.
      Citations: 9     Fields:    Translation:HumansCellsCTClinical Trials
    37. McGahey KE, Weiss GJ. Reviewing concomitant medications for participants in oncology clinical trials. Am J Health Syst Pharm. 2017 Apr 15; 74(8):580-586. PMID: 28389457.
      Citations: 5     Fields:    Translation:Humans
    38. Oellerich M, Schütz E, Beck J, Kanzow P, Plowman PN, Weiss GJ, Walson PD. Using circulating cell-free DNA to monitor personalized cancer therapy. Crit Rev Clin Lab Sci. 2017 05; 54(3):205-218. PMID: 28393575.
      Citations: 41     Fields:    Translation:Humans
    39. Weiss GJ, Beck J, Braun DP, Bornemann-Kolatzki K, Barilla H, Cubello R, Quan W, Sangal A, Khemka V, Waypa J, Mitchell WM, Urnovitz H, Schütz E. Tumor Cell-Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy. Clin Cancer Res. 2017 Sep 01; 23(17):5074-5081. PMID: 28320758.
      Citations: 53     Fields:    Translation:HumansCells
    40. Burris HA, Bakewell S, Bendell JC, Infante J, Jones SF, Spigel DR, Weiss GJ, Ramanathan RK, Ogden A, Von Hoff D. Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in-human, open-label, dose-escalation phase I study with expansion cohort. ESMO Open. 2016; 1(6):e000154. PMID: 28848672.
      Citations:    
    41. Arnold SM, Chansky K, Leggas M, Thompson MA, Villano JL, Hamm J, Sanborn RE, Weiss GJ, Chatta G, Baggstrom MQ. Phase 1b trial of proteasome inhibitor carfilzomib with irinotecan in lung cancer and other irinotecan-sensitive malignancies that have progressed on prior therapy (Onyx IST reference number: CAR-IST-553). Invest New Drugs. 2017 10; 35(5):608-615. PMID: 28204981.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    42. Gettinger SN, Bazhenova LA, Langer CJ, Salgia R, Gold KA, Rosell R, Shaw AT, Weiss GJ, Tugnait M, Narasimhan NI, Dorer DJ, Kerstein D, Rivera VM, Clackson T, Haluska FG, Camidge DR. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Lancet Oncol. 2016 Dec; 17(12):1683-1696. PMID: 27836716.
      Citations: 113     Fields:    Translation:HumansCTClinical Trials
    43. Markman M, Kramer K, Alvarez RH, Weiss GJ, Ahn E, Daneker GW. Evaluating the Utility of a 'N-of-1' Precision Cancer Medicine Strategy: The Case for 'Time-to-Subsequent-Disease Progression'. Oncology. 2016; 91(6):299-301. PMID: 27705967.
      Citations: 2     Fields:    Translation:Humans
    44. Von Hoff DD, Mita MM, Ramanathan RK, Weiss GJ, Mita AC, LoRusso PM, Burris HA, Hart LL, Low SC, Parsons DM, Zale SE, Summa JM, Youssoufian H, Sachdev JC. Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors. Clin Cancer Res. 2016 07 01; 22(13):3157-63. PMID: 26847057.
      Citations: 71     Fields:    Translation:HumansCTClinical Trials
    45. Lohinai Z, Dome P, Szilagyi Z, Ostoros G, Moldvay J, Hegedus B, Dome B, Weiss GJ. From Bench to Bedside: Attempt to Evaluate Repositioning of Drugs in the Treatment of Metastatic Small Cell Lung Cancer (SCLC). PLoS One. 2016; 11(1):e0144797. PMID: 26735301.
      Citations: 9     Fields:    Translation:Humans
    46. Weiss GJ. Precision medicine: lessons learned from the SHIVA trial. Lancet Oncol. 2015 Dec; 16(16):e580. PMID: 26678199.
      Citations: 1     Fields:    Translation:Humans
    47. Salanti A, Clausen TM, Agerbæk MØ, Al Nakouzi N, Dahlbäck M, Oo HZ, Lee S, Gustavsson T, Rich JR, Hedberg BJ, Mao Y, Barington L, Pereira MA, LoBello J, Endo M, Fazli L, Soden J, Wang CK, Sander AF, Dagil R, Thrane S, Holst PJ, Meng L, Favero F, Weiss GJ, Nielsen MA, Freeth J, Nielsen TO, Zaia J, Tran NL, Trent J, Babcook JS, Theander TG, Sorensen PH, Daugaard M. Targeting Human Cancer by a Glycosaminoglycan Binding Malaria Protein. Cancer Cell. 2015 10 12; 28(4):500-514. PMID: 26461094.
      Citations: 80     Fields:    Translation:HumansAnimalsCells
    48. Patnaik A, Weiss GJ, Leonard JE, Rasco DW, Sachdev JC, Fisher TL, Winter LA, Reilly C, Parker RB, Mutz D, Blaydorn L, Tolcher AW, Zauderer M, Ramanathan RK. Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Solid Tumors. Clin Cancer Res. 2016 Feb 15; 22(4):827-36. PMID: 26446947.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    49. Sarantopoulos J, Shapiro GI, Cohen RB, Clark JW, Kauh JS, Weiss GJ, Cleary JM, Mahalingam D, Pickard MD, Faessel HM, Berger AJ, Burke K, Mulligan G, Dezube BJ, Harvey RD. Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors. Clin Cancer Res. 2016 Feb 15; 22(4):847-57. PMID: 26423795.
      Citations: 68     Fields:    Translation:HumansCTClinical Trials
    50. Weiss GJ, Khemka V. Comparing two assays for clinical genomic profiling: the devil is in the data [Letter of clarification]. Onco Targets Ther. 2015; 8:2643. PMID: 26425099.
      Citations:    
    51. Tap WD, Wainberg ZA, Anthony SP, Ibrahim PN, Zhang C, Healey JH, Chmielowski B, Staddon AP, Cohn AL, Shapiro GI, Keedy VL, Singh AS, Puzanov I, Kwak EL, Wagner AJ, Von Hoff DD, Weiss GJ, Ramanathan RK, Zhang J, Habets G, Zhang Y, Burton EA, Visor G, Sanftner L, Severson P, Nguyen H, Kim MJ, Marimuthu A, Tsang G, Shellooe R, Gee C, West BL, Hirth P, Nolop K, van de Rijn M, Hsu HH, Peterfy C, Lin PS, Tong-Starksen S, Bollag G. Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. N Engl J Med. 2015 Jul 30; 373(5):428-37. PMID: 26222558.
      Citations: 164     Fields:    Translation:HumansCTClinical Trials
    52. Patnaik A, Tolcher A, Beeram M, Nemunaitis J, Weiss GJ, Bhalla K, Agrawal M, Nichols G, Middleton S, Beryozkina A, Sarapa N, Peck R, Zhi J. Clinical pharmacology characterization of RG7112, an MDM2 antagonist, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2015 Sep; 76(3):587-95. PMID: 26210682.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    53. Weiss GJ. Influence of Robotic-Assisted Surgery on Readmission Burden. J Clin Oncol. 2015 Jul 01; 33(19):2229. PMID: 26014299.
      Citations:    Fields:    Translation:Humans
    54. Weiss GJ, Hoff BR, Whitehead RP, Sangal A, Gingrich SA, Penny RJ, Mallery DW, Morris SM, Thompson EJ, Loesch DM, Khemka V. Evaluation and comparison of two commercially available targeted next-generation sequencing platforms to assist oncology decision making. Onco Targets Ther. 2015; 8:959-67. PMID: 25960669.
      Citations:    
    55. Dearing KR, Weiss GJ. Translating next-generation sequencing from clinical trials to clinical practice for the treatment of advanced cancers. Per Med. 2015 Mar; 12(2):155-162. PMID: 29754537.
      Citations:    Fields:    
    56. Infante JR, Weiss GJ, Jones S, Tibes R, Bauer TM, Bendell JC, Hinson JM, Von Hoff DD, Burris HA, Orlemans EO, Ramanathan RK. Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours. Eur J Cancer. 2014 Nov; 50(17):2897-904. PMID: 25262379.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    57. Tran JQ, Dranikov A, Iannucci A, Wagner WP, LoBello J, Allen J, Weiss GJ. Heavy Metal Content in Thoracic Tissue Samples from Patients with and without NSCLC. Lung Cancer Int. 2014; 2014:853158. PMID: 26316947.
      Citations:    
    58. Weiss GJ, Ganeshan B, Miles KA, Campbell DH, Cheung PY, Frank S, Korn RL. Noninvasive image texture analysis differentiates K-ras mutation from pan-wildtype NSCLC and is prognostic. PLoS One. 2014; 9(7):e100244. PMID: 24987838.
      Citations: 51     Fields:    Translation:Humans
    59. Yamamoto S, Korn RL, Oklu R, Migdal C, Gotway MB, Weiss GJ, Iafrate AJ, Kim DW, Kuo MD. ALK molecular phenotype in non-small cell lung cancer: CT radiogenomic characterization. Radiology. 2014 Aug; 272(2):568-76. PMID: 24885982.
      Citations: 62     Fields:    Translation:HumansCTClinical Trials
    60. Dearing KR, Sangal A, Weiss GJ. Maintaining clarity: Review of maintenance therapy in non-small cell lung cancer. World J Clin Oncol. 2014 May 10; 5(2):103-13. PMID: 24829857.
      Citations:    
    61. Northfelt DW, Ramanathan RK, Cohen PA, Von Hoff DD, Weiss GJ, Dietsch GN, Manjarrez KL, Randall TD, Hershberg RM. A phase I dose-finding study of the novel Toll-like receptor 8 agonist VTX-2337 in adult subjects with advanced solid tumors or lymphoma. Clin Cancer Res. 2014 Jul 15; 20(14):3683-91. PMID: 24807889.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    62. Whitsett TG, Fortin Ensign SP, Dhruv HD, Inge LJ, Kurywchak P, Wolf KK, LoBello J, Kingsley CB, Allen JW, Weiss GJ, Tran NL. FN14 expression correlates with MET in NSCLC and promotes MET-driven cell invasion. Clin Exp Metastasis. 2014 Aug; 31(6):613-23. PMID: 24710956.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    63. Curtis KK, Sarantopoulos J, Northfelt DW, Weiss GJ, Barnhart KM, Whisnant JK, Leuschner C, Alila H, Borad MJ, Ramanathan RK. Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors. Cancer Chemother Pharmacol. 2014 May; 73(5):931-41. PMID: 24610297.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    64. Whitsett TG, Mathews IT, Cardone MH, Lena RJ, Pierceall WE, Bittner M, Sima C, LoBello J, Weiss GJ, Tran NL. Mcl-1 mediates TWEAK/Fn14-induced non-small cell lung cancer survival and therapeutic response. Mol Cancer Res. 2014 Apr; 12(4):550-9. PMID: 24469836.
      Citations: 19     Fields:    Translation:HumansCells
    65. Dearing KR, Weiss GJ. Molecular characterization may be of PARAMOUNT importance. J Clin Oncol. 2014 Feb 10; 32(5):481-2. PMID: 24395858.
      Citations: 1     Fields:    Translation:Humans
    66. Chang AL, Solomon JA, Hainsworth JD, Goldberg L, McKenna E, Day BM, Chen DM, Weiss GJ. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. J Am Acad Dermatol. 2014 Jan; 70(1):60-9. PMID: 24189279.
      Citations: 41     Fields:    Translation:HumansCTClinical Trials
    67. Weiss GJ, Liang WS, Demeure MJ, Kiefer JA, Hostetter G, Izatt T, Sinari S, Christoforides A, Aldrich J, Kurdoglu A, Phillips L, Benson H, Reiman R, Baker A, Marsh V, Von Hoff DD, Carpten JD, Craig DW. A pilot study using next-generation sequencing in advanced cancers: feasibility and challenges. PLoS One. 2013; 8(10):e76438. PMID: 24204627.
      Citations: 17     Fields:    Translation:HumansCells
    68. Kim TY, Jackson S, Xiong Y, Whitsett TG, Lobello JR, Weiss GJ, Tran NL, Bang YJ, Der CJ. CRL4A-FBXW5-mediated degradation of DLC1 Rho GTPase-activating protein tumor suppressor promotes non-small cell lung cancer cell growth. Proc Natl Acad Sci U S A. 2013 Oct 15; 110(42):16868-73. PMID: 24082123.
      Citations: 33     Fields:    Translation:HumansCells
    69. Liang WS, Aldrich J, Tembe W, Kurdoglu A, Cherni I, Phillips L, Reiman R, Baker A, Weiss GJ, Carpten JD, Craig DW. Long insert whole genome sequencing for copy number variant and translocation detection. Nucleic Acids Res. 2014 Jan; 42(2):e8. PMID: 24071583.
      Citations: 12     Fields:    Translation:Humans
    70. Weiss GJ, Liman AK, Allen J, Cheung PY, Kukunoor RN. Squamous Cell Carcinoma of the Lung with Metastasis to the GI Tract Associated with EGFR Exon 19 Deletion. Case Rep Med. 2013; 2013:874836. PMID: 24171005.
      Citations:    
    71. Whitsett TG, Inge LJ, Dhruv HD, Cheung PY, Weiss GJ, Bremner RM, Winkles JA, Tran NL. Molecular determinants of lung cancer metastasis to the central nervous system. Transl Lung Cancer Res. 2013 Aug; 2(4):273-83. PMID: 25806243.
      Citations:    
    72. McKane A, Sima C, Fleck S, Weiss GJ. Examining the effect of teleconferences on oncology phase 1 trials. J Cancer. 2013; 4(6):464-7. PMID: 23901345.
      Citations:    
    73. Mahadevan D, Chalasani P, Rensvold D, Kurtin S, Pretzinger C, Jolivet J, Ramanathan RK, Von Hoff DD, Weiss GJ. Phase I trial of AEG35156 an antisense oligonucleotide to XIAP plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma. Am J Clin Oncol. 2013 Jun; 36(3):239-43. PMID: 22441342.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    74. Christoforides A, Carpten JD, Weiss GJ, Demeure MJ, Von Hoff DD, Craig DW. Identification of somatic mutations in cancer through Bayesian-based analysis of sequenced genome pairs. BMC Genomics. 2013 May 04; 14:302. PMID: 23642077.
      Citations: 44     Fields:    Translation:Humans
    75. Jimeno A, Weiss GJ, Miller WH, Gettinger S, Eigl BJ, Chang AL, Dunbar J, Devens S, Faia K, Skliris G, Kutok J, Lewis KD, Tibes R, Sharfman WH, Ross RW, Rudin CM. Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. Clin Cancer Res. 2013 May 15; 19(10):2766-74. PMID: 23575478.
      Citations: 76     Fields:    Translation:HumansCellsCTClinical Trials
    76. Caldwell S, Sima C, Jameson G, Fleck S, Weiss GJ. Factors influencing time to determination of the recommended phase 2 dose in phase 1 clinical trials. Am J Clin Oncol. 2013 Apr; 36(2):146-50. PMID: 22314002.
      Citations: 2     Fields:    Translation:Humans
    77. Weekes CD, Von Hoff DD, Adjei AA, Leffingwell DP, Eckhardt SG, Gore L, Lewis KD, Weiss GJ, Ramanathan RK, Dy GK, Ma WW, Sheedy B, Iverson C, Miner JN, Shen Z, Yeh LT, Dubowy RL, Jeffers M, Rajagopalan P, Clendeninn NJ. Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer. Clin Cancer Res. 2013 Mar 01; 19(5):1232-43. PMID: 23434733.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    78. Kurywchak P, Kiefer J, Lenkiewicz E, Evers L, Holley T, Barrett M, Weiss GJ. Elucidating potentially significant genomic regions involved in the initiation and progression of undifferentiated pleomorphic sarcoma. Rare Tumors. 2013 Feb 11; 5(1):e14. PMID: 23772300.
      Citations:    
    79. Weiss GJ, Chao J, Neidhart JD, Ramanathan RK, Bassett D, Neidhart JA, Choi CHJ, Chow W, Chung V, Forman SJ, Garmey E, Hwang J, Kalinoski DL, Koczywas M, Longmate J, Melton RJ, Morgan R, Oliver J, Peterkin JJ, Ryan JL, Schluep T, Synold TW, Twardowski P, Davis ME, Yen Y. First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies. Invest New Drugs. 2013 Aug; 31(4):986-1000. PMID: 23397498.
      Citations: 51     Fields:    Translation:HumansCTClinical Trials
    80. Tabernero J, Shapiro GI, LoRusso PM, Cervantes A, Schwartz GK, Weiss GJ, Paz-Ares L, Cho DC, Infante JR, Alsina M, Gounder MM, Falzone R, Harrop J, White AC, Toudjarska I, Bumcrot D, Meyers RE, Hinkle G, Svrzikapa N, Hutabarat RM, Clausen VA, Cehelsky J, Nochur SV, Gamba-Vitalo C, Vaishnaw AK, Sah DW, Gollob JA, Burris HA. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov. 2013 Apr; 3(4):406-17. PMID: 23358650.
      Citations: 222     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    81. Deeken JF, Slack R, Weiss GJ, Ramanathan RK, Pishvaian MJ, Hwang J, Lewandowski K, Subramaniam D, He AR, Cotarla I, Rahman A, Marshall JL. A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies. Cancer Chemother Pharmacol. 2013 Mar; 71(3):627-33. PMID: 23274395.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    82. Weiss GJ, Korn RL. Interpretation of PET scans: do not take SUVs at face value. J Thorac Oncol. 2012 Dec; 7(12):1744-1746. PMID: 23154544.
      Citations: 2     Fields:    Translation:Humans
    83. Weiss GJ. Doubling down with inhibitors of Notch and Hedgehog signaling pathways. J Thorac Oncol. 2012 Dec; 7(16 Suppl 5):S409-10. PMID: 23160337.
      Citations:    Fields:    Translation:HumansCells
    84. Mckane A, Sima C, Ramanathan RK, Jameson G, Mast C, White E, Fleck S, Downhour M, Von Hoff DD, Weiss GJ. Determinants of patient screen failures in Phase 1 clinical trials. Invest New Drugs. 2013 Jun; 31(3):774-9. PMID: 23135779.
      Citations: 4     Fields:    Translation:Humans
    85. Jameson GS, Hamm JT, Weiss GJ, Alemany C, Anthony S, Basche M, Ramanathan RK, Borad MJ, Tibes R, Cohn A, Hinshaw I, Jotte R, Rosen LS, Hoch U, Eldon MA, Medve R, Schroeder K, White E, Von Hoff DD. A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors. Clin Cancer Res. 2013 Jan 01; 19(1):268-78. PMID: 23136196.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    86. Liang WS, Craig DW, Carpten J, Borad MJ, Demeure MJ, Weiss GJ, Izatt T, Sinari S, Christoforides A, Aldrich J, Kurdoglu A, Barrett M, Phillips L, Benson H, Tembe W, Braggio E, Kiefer JA, Legendre C, Posner R, Hostetter GH, Baker A, Egan JB, Han H, Lake D, Stites EC, Ramanathan RK, Fonseca R, Stewart AK, Von Hoff D. Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing. PLoS One. 2012; 7(10):e43192. PMID: 23071490.
      Citations: 36     Fields:    Translation:HumansCells
    87. Gordon MS, Rosen LS, Mendelson D, Ramanathan RK, Goldman J, Liu L, Xu Y, Gerson SL, Anthony SP, Figg WD, Spencer S, Adams BJ, Theuer CP, Leigh BR, Weiss GJ. A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors. Invest New Drugs. 2013 Jun; 31(3):714-23. PMID: 23054206.
      Citations: 12     Fields:    Translation:HumansCellsCTClinical Trials
    88. Arora S, Korn RL, Lenkiewicz E, Cherni I, Beach TG, Hostetter G, Barrett MT, Weiss GJ. Clonal evolution of a case of treatment refractory maxillary sinus carcinoma. PLoS One. 2012; 7(9):e45614. PMID: 23029135.
      Citations: 2     Fields:    Translation:Humans
    89. Thacker CA, Weiss GJ, Tibes R, Blaydorn L, Downhour M, White E, Baldwin J, Hoff DD, Korn RL. 18-FDG PET/CT assessment of basal cell carcinoma with vismodegib. Cancer Med. 2012 Oct; 1(2):230-6. PMID: 23342272.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    90. Whitsett TG, Cheng E, Inge L, Asrani K, Jameson NM, Hostetter G, Weiss GJ, Kingsley CB, Loftus JC, Bremner R, Tran NL, Winkles JA. Elevated expression of Fn14 in non-small cell lung cancer correlates with activated EGFR and promotes tumor cell migration and invasion. Am J Pathol. 2012 Jul; 181(1):111-20. PMID: 22634180.
      Citations: 26     Fields:    Translation:HumansAnimalsCells
    91. Weiss GJ, Liang WS, Izatt T, Arora S, Cherni I, Raju RN, Hostetter G, Kurdoglu A, Christoforides A, Sinari S, Baker AS, Metpally R, Tembe WD, Phillips L, Von Hoff DD, Craig DW, Carpten JD. Paired tumor and normal whole genome sequencing of metastatic olfactory neuroblastoma. PLoS One. 2012; 7(5):e37029. PMID: 22649506.
      Citations: 16     Fields:    Translation:HumansCells
    92. Weiss GJ, Korn RL. Metastatic basal cell carcinoma in the era of hedgehog signaling pathway inhibitors. Cancer. 2012 Nov 01; 118(21):5310-9. PMID: 22511370.
      Citations: 13     Fields:    Translation:HumansCells
    93. Weiss GJ, Donehower RC, Iyengar T, Ramanathan RK, Lewandowski K, Westin E, Hurt K, Hynes SM, Anthony SP, McKane S. Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer. Invest New Drugs. 2013 Feb; 31(1):136-44. PMID: 22492020.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    94. Looyenga BD, Hutchings D, Cherni I, Kingsley C, Weiss GJ, Mackeigan JP. STAT3 is activated by JAK2 independent of key oncogenic driver mutations in non-small cell lung carcinoma. PLoS One. 2012; 7(2):e30820. PMID: 22319590.
      Citations: 62     Fields:    Translation:HumansCells
    95. Cheung PY, Szafranska-Schwarzbach AE, Schlageter AM, Andruss BF, Weiss GJ. No miR quirk: dysregulation of microRNAs in pancreatic ductal adenocarcinoma. Microrna. 2012; 1(1):49-58. PMID: 25048090.
      Citations:    Fields:    Translation:Humans
    96. Sheff KW, Hoda MA, Dome B, Hegedus B, Klepetko W, Weiss GJ. The role of microRNAs in the diagnosis and treatment of malignant pleural mesothelioma--a short review. Microrna. 2012; 1(1):40-8. PMID: 25048089.
      Citations:    Fields:    Translation:Humans
    97. Weiss GJ, Hidalgo M, Borad MJ, Laheru D, Tibes R, Ramanathan RK, Blaydorn L, Jameson G, Jimeno A, Isaacs JD, Scaburri A, Pacciarini MA, Fiorentini F, Ciomei M, Von Hoff DD. Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies. Invest New Drugs. 2012 Dec; 30(6):2334-43. PMID: 22160853.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    98. Weiss GJ, Mita AC, Von Hoff DD. The hedgehog knows many tricks. Curr Drug Targets. 2011 Dec; 12(14):2091-5. PMID: 21777197.
      Citations:    Fields:    Translation:HumansAnimalsCells
    99. Bailey CH, Jameson G, Sima C, Fleck S, White E, Von Hoff DD, Weiss GJ. Progression-free Survival Decreases with Each Subsequent Therapy in Patients Presenting for Phase I Clinical Trials. J Cancer. 2012; 3:7-13. PMID: 22211140.
      Citations:    
    100. Raz G, Allen KE, Kingsley C, Cherni I, Arora S, Watanabe A, Lorenzo CD, Edwards V DK, Sridhar S, Hostetter G, Weiss GJ. Hedgehog signaling pathway molecules and ALDH1A1 expression in early-stage non-small cell lung cancer. Lung Cancer. 2012 May; 76(2):191-6. PMID: 22115706.
      Citations: 25     Fields:    Translation:HumansCells
    101. Weiss GJ. Targeting the Hedgehog and Notch signaling pathways. J Thorac Oncol. 2011 Nov; 6(11 Suppl 4):S1820-1. PMID: 22005544.
      Citations:    Fields:    Translation:HumansCells
    102. Bailey CH, Donovan PJ, Weiss GJ. Basal cell adenocarcinoma of the supraglottic larynx: treatment of recurrent disease with tamoxifen. Rare Tumors. 2011 Oct 21; 3(4):e55. PMID: 22355510.
      Citations:    
    103. Weiss GJ, Tibes R, Blaydorn L, Jameson G, Downhour M, White E, Caro I, Von Hoff DD. Long-term safety, tolerability, and efficacy of vismodegib in two patients with metastatic basal cell carcinoma and basal cell nevus syndrome. Dermatol Reports. 2011 Oct 05; 3(3):e55. PMID: 25386306.
      Citations:    
    104. Weiss GJ, Lewandowski K, Oneall J, Kroll S. Resolution of Cullen's sign in patient with metastatic melanoma responding to hypoxia-activated prodrug TH-302. Dermatol Reports. 2011 Oct 05; 3(3):e56. PMID: 25386307.
      Citations:    
    105. Cherni I, Weiss GJ. miRNAs in lung cancer: large roles for small players. Future Oncol. 2011 Sep; 7(9):1045-55. PMID: 21919692.
      Citations: 17     Fields:    Translation:Humans
    106. Ramanathan RK, Stephenson JJ, Weiss GJ, Pestano LA, Lowe A, Hiscox A, Leos RA, Martin JC, Kirkpatrick L, Richards DA. A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy. Invest New Drugs. 2012 Aug; 30(4):1591-6. PMID: 21863237.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    107. Looyenga BD, Cherni I, Mackeigan JP, Weiss GJ. Tailoring tyrosine kinase inhibitors to fit the lung cancer genome. Transl Oncol. 2011 Apr 01; 4(2):59-70. PMID: 21461169.
      Citations:    
    108. Arora S, Ranade AR, Tran NL, Nasser S, Sridhar S, Korn RL, Ross JT, Dhruv H, Foss KM, Sibenaller Z, Ryken T, Gotway MB, Kim S, Weiss GJ. MicroRNA-328 is associated with (non-small) cell lung cancer (NSCLC) brain metastasis and mediates NSCLC migration. Int J Cancer. 2011 Dec 01; 129(11):2621-31. PMID: 21448905.
      Citations: 89     Fields:    Translation:HumansCells
    109. Weiss GJ, Infante JR, Chiorean EG, Borad MJ, Bendell JC, Molina JR, Tibes R, Ramanathan RK, Lewandowski K, Jones SF, Lacouture ME, Langmuir VK, Lee H, Kroll S, Burris HA. Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies. Clin Cancer Res. 2011 May 01; 17(9):2997-3004. PMID: 21415214.
      Citations: 64     Fields:    Translation:HumansCTClinical Trials
    110. Foss KM, Sima C, Ugolini D, Neri M, Allen KE, Weiss GJ. miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer. J Thorac Oncol. 2011 Mar; 6(3):482-8. PMID: 21258252.
      Citations: 127     Fields:    Translation:Humans
    111. LoRusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Chang I, Darbonne WC, Graham RA, Zerivitz KL, Low JA, Von Hoff DD. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res. 2011 Apr 15; 17(8):2502-11. PMID: 21300762.
      Citations: 209     Fields:    Translation:HumansCellsCTClinical Trials
    112. Shapiro GI, Tibes R, Gordon MS, Wong BY, Eder JP, Borad MJ, Mendelson DS, Vogelzang NJ, Bastos BR, Weiss GJ, Fernandez C, Sutherland W, Sato H, Pierceall WE, Weaver D, Slough S, Wasserman E, Kufe DW, Von Hoff D, Kawabe T, Sharma S. Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumors. Clin Cancer Res. 2011 May 15; 17(10):3431-42. PMID: 21220472.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    113. Ranade AR, Weiss GJ. Methods for microRNA microarray profiling. Methods Mol Biol. 2011; 700:145-52. PMID: 21204032.
      Citations: 2     Fields:    Translation:HumansCells
    114. Nasser S, Ranade AR, Sridhar S, Haney L, Korn RL, Gotway MB, Weiss GJ, Kim S. Biomarkers associated with metastasis of lung cancer to brain predict patient survival. Int J Data Min Bioinform. 2011; 5(3):287-307. PMID: 21805824.
      Citations: 3     Fields:    Translation:Humans
    115. Allen KE, Weiss GJ. Resistance may not be futile: microRNA biomarkers for chemoresistance and potential therapeutics. Mol Cancer Ther. 2010 Dec; 9(12):3126-36. PMID: 20940321.
      Citations: 76     Fields:    Translation:HumansAnimalsCells
    116. Weiss GJ, Alarcon A, Halepota M, Penny RJ, Von Hoff DD. Molecular characterization of interdigitating dendritic cell sarcoma. Rare Tumors. 2010 Sep 30; 2(3):e50. PMID: 21139965.
      Citations:    
    117. Weiss GJ. Thymic carcinoma: current and future therapeutic interventions. Expert Opin Investig Drugs. 2010 Aug; 19(8):1007-16. PMID: 20629617.
      Citations: 4     Fields:    Translation:Humans
    118. Ranade AR, Cherba D, Sridhar S, Richardson P, Webb C, Paripati A, Bowles B, Weiss GJ. MicroRNA 92a-2*: a biomarker predictive for chemoresistance and prognostic for survival in patients with small cell lung cancer. J Thorac Oncol. 2010 Aug; 5(8):1273-8. PMID: 20548249.
      Citations: 41     Fields:    Translation:Humans
    119. Goldberg LH, Firoz BF, Weiss GJ, Blaydorn L, Jameson G, Von Hoff DD. Basal cell nevus syndrome: a brave new world. Arch Dermatol. 2010 Jan; 146(1):17-9. PMID: 20083687.
      Citations: 1     Fields:    Translation:Humans
    120. Paripati A, Kingsley C, Weiss GJ. Pathway targets to explore in the treatment of small cell and large cell lung cancers. J Thorac Oncol. 2009 Nov; 4(11):1313-21. PMID: 19812504.
      Citations: 2     Fields:    Translation:HumansCells
    121. Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Mackey HM, Lum BL, Darbonne WC, Marsters JC, de Sauvage FJ, Low JA. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009 Sep 17; 361(12):1164-72. PMID: 19726763.
      Citations: 402     Fields:    Translation:HumansCellsCTClinical Trials
    122. Nelson KM, Weiss GJ. MicroRNAs and cancer: past, present, and potential future. Mol Cancer Ther. 2008 Dec; 7(12):3655-60. PMID: 19074842.
      Citations: 122     Fields:    Translation:HumansAnimalsCells
    123. Weiss GJ, Kingsley C. Pathway targets to explore in the treatment of non-small cell lung cancer. J Thorac Oncol. 2008 Nov; 3(11):1342-52. PMID: 18978571.
      Citations: 4     Fields:    Translation:HumansCells
    124. Weiss GJ. Continuous-flow ventricular assist device. N Engl J Med. 2007 Nov 29; 357(22):2305; author reply 2305-6. PMID: 18046035.
      Citations:    Fields:    Translation:Humans
    125. Weiss GJ, Vokes EE, Bunn PA, Magree L, Rusk J, Albert D, Kelly K. Docetaxel and exisulind in previously treated non-small cell lung cancer (NSCLC) patients: a multicenter, phase II clinical trial. J Thorac Oncol. 2007 Oct; 2(10):933-8. PMID: 17909356.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    126. Weiss GJ, Zeng C, Kelly K, Tran ZV, Bunn PA. Single-institution experience with pemetrexed and bevacizumab as salvage therapy in advanced non-small-cell lung cancer. Clin Lung Cancer. 2007 Mar; 8(5):335-8. PMID: 17562234.
      Citations: 5     Fields:    Translation:Humans
    127. Escobar GA, Robinson WA, Nydam TL, Heiple DC, Weiss GJ, Buckley L, Gonzalez R, McCarter MD. Severe paraneoplastic hypoglycemia in a patient with a gastrointestinal stromal tumor with an exon 9 mutation: a case report. BMC Cancer. 2007 Jan 17; 7:13. PMID: 17229322.
      Citations: 10     Fields:    Translation:Humans
    128. Weiss GJ, Bunn PA, Camidge DR. From radiotherapy to Targeted therapy: 20 years in the management of non-small-cell lung cancer. Oncology (Williston Park). 2006 Nov; 20(12):1515-24; discussion 1524-5, 1530, 1535. PMID: 17153906.
      Citations: 4     Fields:    Translation:Humans
    129. Weiss GJ, Langer C, Rosell R, Hanna N, Shepherd F, Einhorn LH, Nguyen B, Paul S, McAndrews P, Bunn PA, Kelly K. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2006 Sep 20; 24(27):4405-11. PMID: 16983108.
      Citations: 41     Fields:    Translation:Humans
    130. Weiss G, Shemer A, Trau H. Yellowish, verrucous lesions on the scalp. Am Fam Physician. 2005 Mar 01; 71(5):961-2. PMID: 15768626.
      Citations:    Fields:    Translation:Humans
    131. Weiss G, Confino Y, Shemer A, Trau H. Cutaneous manifestations in the cardiofaciocutaneous syndrome, a variant of the classical Noonan syndrome. Report of a case and review of the literature. J Eur Acad Dermatol Venereol. 2004 May; 18(3):324-7. PMID: 15096145.
      Citations: 6     Fields:    Translation:Humans
    132. Rogachefsky AS, Becker K, Weiss G, Goldberg DJ. Evaluation of a long-pulsed Nd:YAG laser at different parameters: an analysis of both fluence and pulse duration. Dermatol Surg. 2002 Oct; 28(10):932-5; discussion 936. PMID: 12410678.
      Citations: 2     Fields:    Translation:Humans
    133. Shemer A, Weiss G, Trau H. Oral terbinafine in the treatment of onychomycosis: a comparison of continuous and extended-pause regimens. J Eur Acad Dermatol Venereol. 2002 May; 16(3):299-301. PMID: 12195585.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    134. Weiss G, Shemer A, Trau H. The Koebner phenomenon: review of the literature. J Eur Acad Dermatol Venereol. 2002 May; 16(3):241-8. PMID: 12195563.
      Citations: 62     Fields:    Translation:Humans
    135. Shemer A, Weiss G, Amichai B, Kaplan B, Trau H. Azelaic acid (20%) cream in the treatment of acne vulgaris. J Eur Acad Dermatol Venereol. 2002 Mar; 16(2):178-9. PMID: 12046832.
      Citations: 5     Fields:    Translation:Humans
    136. Shemer A, Weiss G, Confino Y, Trau H. The hyper-IgE syndrome. Two cases and review of the literature. Int J Dermatol. 2001 Oct; 40(10):622-8. PMID: 11737420.
      Citations: 4     Fields:    Translation:Humans
    137. Shemer A, Weiss G, Trau H. Wolf's isotopic response: a case of zosteriform lichen planus on the site of healed herpes zoster. J Eur Acad Dermatol Venereol. 2001 Sep; 15(5):445-7. PMID: 11763387.
      Citations: 3     Fields:    Translation:Humans
    138. Zilinsky I, Winkler E, Weiss G, Haik J, Tamir J, Orenstein A. Total lower lip reconstruction with innervated muscle-bearing flaps: a modification of the Webster flap. Dermatol Surg. 2001 Jul; 27(7):687-91. PMID: 11442627.
      Citations: 4     Fields:    Translation:Humans
    139. Weiss G, Shemer A, Confino Y, Kaplan B, Trau H. Wells' syndrome: report of a case and review of the literature. Int J Dermatol. 2001 Feb; 40(2):148-52. PMID: 11328401.
      Citations: 5     Fields:    Translation:Humans
    140. Cohen B, Weiss G, Yin H. Basal cell carcinoma (BCC) causing spinal cord compression. Dermatol Online J. 2000 Sep; 6(1):12. PMID: 11328622.
      Citations: 3     Fields:    Translation:Humans
    141. Shemer A, Nathansohn N, Kaplan B, Weiss G, Newman N, Trau H. Treatment of scalp seborrheic dermatitis and psoriasis with an ointment of 40% urea and 1% bifonazole. Int J Dermatol. 2000 Jul; 39(7):532-4. PMID: 10940120.
      Citations: 4     Fields:    Translation:Humans
    142. Weiss G, Cohen B. The efficacy of long-term epilation of unwanted hair by noncoherent filtered flashlamp. Lasers Surg Med. 2000; 26(4):345. PMID: 10805938.
      Citations:    Fields:    Translation:Humans
    143. Weiss G, Abramovitch H, Winters SL, Curwin JH, Neglio D, Raquet S, Manlangit ML. Living with an internal cardioverter defibrillator: Assessment of psychosocial factors affecting coping. Online J Cardiol. 1999. View Publication.
    Weiss's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (490)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _